Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.80 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL1268415 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL902046 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL6675043 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL2233580 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL3320717 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL6028716 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL1907826 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Cysteine SCHEMBL28436580 | 0.98 | PTGS1 (0.76) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Aspartic Acid SCHEMBL8628354 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 | |
| Serine SCHEMBL418635 | 0.91 | PTGS1 (0.67) | PTGS1SLC7A11GLRA1SLC6A9OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925977-B2 | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications | Ceil>Point, LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-10814013-B2 | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-27 | — | — | US | disclosed |
| EP-2079486-B1 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | UNIV TEXAS (US) | 2018-04-04 | — | — | EP | disclosed |
| CN-104800862-A | Efficient synthesis, compositions and uses of chelators for nuclear imaging and radiotherapy | UNIV TEXAS | 2015-07-29 | — | — | CN | disclosed |
| US-20130039853-A1 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | CELL>POINT, LLC | 2013-02-14 | — | — | US | disclosed |
| US-20100104511-A1 | METHODS AND COMPOSITIONS USING CHELATOR-ANTIBODY CONJUGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-04-29 | — | — | US | disclosed |
| CN-101678118-A | Efficient synthesis of chelators for nuclear imaging and radiotherapy: composition and use | UNIV TEXAS | 2010-03-24 | — | — | CN | disclosed |
| EP-2079486-A2 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | The Board of Regents of The University of Texas System (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008064040-A2 | METHODS AND COMPOSITIONS USING CHELATOR-ANTIBODY CONJUGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080107598-A1 | Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications | COLIP, GREGORY RUSSELL | 2008-05-08 | — | — | US | disclosed |
| WO-2008045604-A2 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107598-A1 | Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications | TNNI3, CAD, TNNT2 | PTGS1 2845/4885SLC7A11 69/4885GLRA1 1222/4885 |
| US-10814013-B2 | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications | TNNI3, CAD, TNNT2 | PTGS1 2845/4885SLC7A11 69/4885GLRA1 1222/4885 |
| US-10925977-B2 | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications | TNNI3, CAD, TNNT2 | PTGS1 2845/4885SLC7A11 69/4885GLRA1 1222/4885 |
| US-20130039853-A1 | EFFICIENT SYNTHESIS OF CHELATORS FOR NUCLEAR IMAGING AND RADIOTHERAPY: COMPOSITIONS AND APPLICATIONS | TNNI3, CAD, TNNT2 | PTGS1 2845/4885SLC7A11 69/4885GLRA1 1222/4885 |
| US-20100104511-A1 | METHODS AND COMPOSITIONS USING CHELATOR-ANTIBODY CONJUGATES | ERBB2, EGFR, ERBB3 | PTGS1 4822/4885SLC7A11 595/4885GLRA1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.